Takeda Invests in Plasma Facilities in Indonesia, Targets 2027 Operations

Indonesia has welcomed an investment commitment from Japanese biopharmaceutical company Takeda to develop a Plasma-Derived Medicinal Products (PDMP) ecosystem in the country. In the initial phase, Takeda will invest up to US$30 million, approximately Rp 539 billion, over two years to build a plasma bank network as the foundation for developing the national plasma industry. Minister for Investment and Downstreaming/Head of the Investment Coordinating Board (BKPM), Rosan Roeslani, stated that Takeda’s investment reflects growing global investor confidence in Indonesia’s investment prospects, particularly in the high-tech healthcare sector. This strategic investment not only brings additional capital but also opens opportunities for technology transfer, human resource development, and the creation of high-skilled jobs. “The government continues to encourage investments that provide added value and strengthen national industrial capacity so that Indonesia can become a manufacturing and healthcare innovation hub in the region,” Rosan said in an official statement received on Tuesday. This partnership aligns with the economic transformation agenda through downstreaming in various strategic sectors, including healthcare, to enhance national industrial competitiveness and strengthen Indonesia’s position in the global supply chain. Japan is one of Indonesia’s strategic investment partners. According to data from the Ministry of Investment and Downstreaming/BKPM, in the first quarter of 2026, Japan ranked fifth among Indonesia’s top investors, reaching US$1 billion. Total realised investment from Japan from 2021 to the first quarter of 2026 reached US$18.1 billion, with an average growth of 13.2% and employment absorption of 299,460 people. This provides a strong foundation for developing investment cooperation in various priority sectors, including healthcare. Through this collaboration, the government hopes Indonesia will not only improve public access to much-needed plasma-derived medicinal products but also build a competitive, innovative, and sustainable biopharmaceutical industry ecosystem. “The first plasma bank is targeted to begin operations in 2027 as part of developing a national plasma network that meets international standards,” he said.